Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

ABSTRACT:

Purpose

Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) after pembrolizumab treatment in melanoma patients.

Experimental design

Serum lactate dehydrogenase (LDH), routine blood count parameters, and clinical characteristics were investigated in 616 patients. Endpoints were OS and best overall response following pembrolizumab treatment. Kaplan-Meier analysis and Cox regression were applied for survival analysis.

Results

Relative eosinophil count (REC) ≥1.5%, relative lymphocyte count (RLC) ≥17.5%, ≤2.5-fold elevation of LDH, and the absence of metastasis other than soft-tissue/lung were associated wit

SUBMITTER: Weide B 

PROVIDER: S-EPMC5572569 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature